Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and

2011 ◽  
Vol 63 (S11) ◽  
pp. S337-S349 ◽  
Author(s):  
Kenneth Tang ◽  
Dorcas E. Beaton ◽  
Annelies Boonen ◽  
Monique A. M. Gignac ◽  
Claire Bombardier
Keyword(s):  
Rheumatoid Arthritis ◽  
Work Disability ◽  
Work Productivity ◽  
Activity Limitations ◽  
Specific Work ◽  
Work Limitations

scholarly journals Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Cătălin Codreanu ◽  
Corina Mogoșan ◽  
Claudiu Popescu ◽  
Marian-Sorin Paveliu
Keyword(s):  
Rheumatoid Arthritis ◽  
Work Disability ◽  
Disease Duration ◽  
Work Productivity ◽  
Indirect Costs ◽  
Paid Work ◽  
Reported Data ◽  
The Cost ◽  
Permanent Work

Rheumatoid arthritis (RA) is associated with increased costs generated by resource utilization and loss of work productivity. We have studied 206 RA patients and analyzed indirect costs of RA in Romania (estimated using the human capital approach) in comparison with reported data for other countries. Data were collected using self-reported questionnaires. The average age at inclusion was 55 years, with mean disease duration of 9.4 years; 55 patients had permanent work disability due to RA; 6.35 days of sick leave per patient were reported for the entire year of follow-up; the cost of permanent work disability was 1256€ per patient. From a societal perspective, the average indirect costs for a patient with RA were 1506€, significantly lower than the ones reported by other countries, especially due to the low monetary value of paid work.

scholarly journals Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study

2019 ◽  
Vol 11 ◽  
pp. 1759720X1983115
Author(s):  
Louis Bessette ◽  
Boulos Haraoui ◽  
Andrew Chow ◽  
Isabelle Fortin ◽  
Sanjay Dixit ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Real World ◽  
Certolizumab Pegol ◽  
Health Assessment ◽  
Work Productivity ◽  
Primary Objective ◽  
Joint Disease ◽  
Specific Work ◽  
The Impact

Background: The aim of this study was to assess the real-world effectiveness and safety of certolizumab pegol (CZP) in rheumatoid arthritis (RA) patients, and the impact on patients’ productivity, pain, and fatigue, in Canadian practice. Methods: FαsT-CAN, a 2-year prospective, observational study, evaluated CZP use in Canadian adults with moderate to severe, active RA. The primary objective was to assess the proportion of patients achieving 28-joint Disease Activity Scores (DAS28) <2.6 at Week 104. Secondary and additional endpoints assessed the improvements in Patients’ Assessment of Arthritis Pain (PtAAP), fatigue, Health Assessment Questionnaire-Disability Index (HAQ-DI), and the proportion of patients achieving minimal clinically important differences (MCID) in HAQ-DI. Validated arthritis-specific Work Productivity Surveys (WPS-RA) assessed the RA-associated impact on productivity. Incidence of CZP-related treatment-emergent adverse events (TEAEs) was reported for patients receiving ⩾1 dose of CZP (safety set). Results: The full analysis set (baseline DAS28 ⩾ 2.6, ⩾1 dose of CZP and ⩾1 valid post-baseline DAS28 measurement) included 451 of the 546 patients recruited into the study; a total of 229/451 (50.8%) patients completed Week 104. At Week 104, 90/451 (20.0%) patients achieved DAS28 < 2.6. Rapid improvements in disease activity, pain, and fatigue were observed. At Week 104, 66.2% of patients achieved HAQ-DI MCID. Patients employed at Week 104, reported reduced absenteeism, and improved productivity. CZP-related TEAEs were consistent with the known CZP safety profile. Conclusions: CZP was an effective RA treatment in Canadian practice, and no new CZP-related safety signals were identified. The improvements in household and workplace productivity are the first observations in a real-world Canadian setting.

scholarly journals Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis

Rheumatology ◽  
2020 ◽  
Vol 59 (10) ◽  
pp. 2908-2919 ◽  
Author(s):  
James M Gwinnutt ◽  
Sarah Leggett ◽  
Mark Lunt ◽  
Anne Barton ◽  
Kimme L Hyrich ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psychological Distress ◽  
Incidence Rate ◽  
Rate Ratio ◽  
Incidence Rate Ratio ◽  
Work Productivity ◽  
Work Outcomes ◽  
Specific Work ◽  
Work Loss ◽  
Eular Response

Abstract Objectives Work is an important health outcome. This study aimed to identify predictors of work loss, absenteeism and presenteeism over 1 year in RA patients commencing treatment with MTX or biologics. Methods Patients aged 18–65 years in full/part-time employment from two UK prospective cohorts were included: MTX-starters = Rheumatoid Arthritis Medication Study; and biologic-starters = Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate. Presenteeism and absenteeism were assessed using the RA-specific Work Productivity Survey at baseline, and 6 and 12 months. Potential predictors including baseline age, gender, clinical measures (e.g. disability, pain, fatigue), psychological distress, occupation and EULAR response from baseline to 6 months were investigated. Results A total of 51/463 MTX-starters and 30/260 biologic-starters left work over 12 months. Higher baseline psychological distress in MTX-starters [odds ratio (OR) 1.1 (95% CI: 1.0, 1.1)] and higher disability in biologic-starters [OR 3.5 (95% CI: 1.4, 8.6)] predicted work loss. Some 16.1% of patients reported sick-leave, which was predicted by disability [OR (95% CI): MTX-starters: 1.5 (0.9, 2.3); biologic-starters: 2.4 (1.1, 5.2)]. Median presenteeism scores were very low (minimal interference) in both cohorts. Higher fatigue for MTX starters [incidence rate ratio 1.2 (95% CI: 1.0, 1.4)] and higher disability in biologic-starters (incidence rate ratio 1.4 (95% CI: 1.1, 1.7)] predicted presenteeism. Good EULAR response was associated with lower absenteeism and presenteeism in both cohorts. Conclusion Patients with RA still face significant limitations regarding their ability to work. Disability and EULAR response were the main predictors of work outcomes, emphasizing the need to control the disease and the importance of function in enabling work participation.

scholarly journals Effect of Adalimumab on Work Ability Assessed in Rheumatoid Arthritis Disease Patients in Saudi Arabia (AWARDS)

2015 ◽  
Vol 9 (1) ◽  
pp. 46-50 ◽  
Author(s):  
Waleed Hussain ◽  
Nahid Janoudi ◽  
Abdulsalam Noorwali ◽  
Narges Omran ◽  
Matouqa Baamer ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Saudi Arabia ◽  
Work Ability ◽  
Work Disability ◽  
Health Assessment ◽  
Work Productivity ◽  
Long Term Effects ◽  
Activity Impairment ◽  
Rheumatoid Arthritis Disease ◽  
Adalimumab Therapy

Objectives : Rheumatoid arthritis (RA) is a chronic disabling disease that can jeopardize the ability of affected individuals to participate in paid work. Our objective was to evaluate the effectiveness of a 6-month course of tumor necrosis factor (TNF) antagonist (adalimumab) on work ability, overall health, and fatigue in RA patients. Methods : Between October 2012 and February 2014, this prospective, observational study enrolled 63 consecutive patients with established adult RA at outpatient clinics in Makkah, Jeddah, Riyadh and Abha (Saudi Arabia). Patients received subcutaneous injections of adalimumab (40 mg every 2 weeks). Outcomes were measured at baseline and 6 months using the following tools: Work Productivity and Activity Impairment (WPAI), Health Assessment Questionnaire Disability Index (HAQ-DI), Fatigue Severity Scale (FSS), Visual Analog Scale for Fatigue (VAS-F), and work disability self-assessment. Results : All outcomes showed improvements after 6 months of adalimumab therapy. Significant improvements from baseline were observed in absenteeism (64% ± 11.62 to 11.60% ± 11.17 [p<0.0001]), presenteeism (62.15% ± 20.11 to 34.92% ± 20.61 [p<0.0001]), overall work impairment (69.08% ± 18.86 to 40.73% ± 22.29 [p<0.0001]), overall activity impairment (68.46% ± 18.58 to 36.46% ± 20.79 [p<0.0001]), HAQ score (1.69 ± 0.57 to 0.81 ± 0.61 [p<0.0001]), and FSS score (47.08 ± 9.55 to 27.86 ± 13.43 [p<0.0001]). Conclusion : A 6-month course of adalimumab improved work ability, fatigue, and overall health assessments in patients with established RA. Our findings encourage randomized controlled trials investigating the cost-effectiveness and long-term effects of TNF inhibitors on work disability.

scholarly journals Worker Productivity Outcome Measures: OMERACT Filter Evidence and Agenda for Future Research

2013 ◽  
Vol 41 (1) ◽  
pp. 165-176 ◽  
Author(s):  
Kenneth Tang ◽  
Annelies Boonen ◽  
Suzanne M.M. Verstappen ◽  
Reuben Escorpizo ◽  
Jolanda J. Luime ◽  
...  
Keyword(s):  
Outcome Measures ◽  
Working Group ◽  
Work Productivity ◽  
Current Evidence ◽  
Future Research ◽  
Specific Work ◽  
Worker Productivity ◽  
Activity Impairment ◽  
Work Limitations ◽  
The Future

The objective of the Outcome Measures in Rheumatology (OMERACT) Worker Productivity working group is to identify worker productivity outcome measures that meet the requirements of the OMERACT filter. At the OMERACT 11 Workshop, we focused on the at-work limitations/productivity component of worker productivity (i.e., presenteeism) — an area with diverse conceptualization and instrumentation approaches. Various approaches to quantify at-work limitations/productivity (e.g., single-item global and multi-item measures) were examined, and available evidence pertaining to OMERACT truth, discrimination, and feasibility were presented to conference participants. Four candidate global measures of presenteeism were put forth for a plenary vote to determine whether current evidence meets the OMERACT filter requirements. Presenteeism globals from the Work Productivity and Activity Impairment Questionnaire (72% support) and Rheumatoid Arthritis-specific Work Productivity Survey (71% support) were endorsed by conference participants; however, neither the presenteeism global item from the Health and Work Performance Questionnaire nor the Quantity and Quality method achieved the level of support required for endorsement at the present time. The plenary was also asked whether the central item from the Work Ability Index should also be considered as a candidate measure for potential endorsement in the future. Of participants at the plenary, 70% supported this presenteeism global measure. Progress was also made in other areas through discussions at individual breakout sessions. Topics examined include the merits of various multi-item measures of at-work limitations/productivity, methodological issues related to interpretability of outcome scores, and approaches to appraise and classify contextual factors of worker productivity. Feedback gathered from conference participants will inform the future research agenda of the working group.

scholarly journals Pain in Multiple Sites and Clusters of Cause-Specific Work Disability Development among Midlife Municipal Employees

2021 ◽  
Vol 18 (7) ◽  
pp. 3375
Author(s):  
Aapo Hiilamo ◽  
Anna Huttu ◽  
Simon Øverland ◽  
Olli Pietiläinen ◽  
Ossi Rahkonen ◽  
...  
Keyword(s):  
Work Disability ◽  
Multinomial Logistic Regression ◽  
Health Behaviours ◽  
Health Study ◽  
Specific Work ◽  
Prevention Measures ◽  
Occupational Class ◽  
Work Disability Prevention ◽  
Municipal Employees ◽  
Adjusted Model

This study investigates to what extent pain in multiple sites and common risk factors related to work environment, occupational class and health behaviours are associated with cause-specific work disability (WD) development clusters. The study population was derived from the Finnish Helsinki Health Study (n = 2878). Sequence analysis created clusters of similar subsequent cause-specific WD development in an eight-year follow-up period. Cross-tabulations and multinomial logistic regression were used to analyze the extent to which baseline factors, including pain in multiple sites, were associated with the subsequent WD clusters. A solution with five distinct WD clusters was chosen: absence of any WD (40%), low and temporary WD due to various causes (46%), WD due to mental disorders (3%), WD due to musculoskeletal (8%) and WD due to other causes (4%). Half of the employees in the musculoskeletal WD cluster had pain in multiple locations. In the adjusted model the number of pain sites, low occupational class and physical working conditions were linked to the musculoskeletal WD. The identified characteristics of the different WD clusters may help target tailored work disability prevention measures for those at risk.

Sign in / Sign up

Export Citation Format

Share Document